Good news for people newly diagnosed with rare autoimmune disorder: Study finds low relapse risk

AI Summary

A Kaiser Permanente study found that people newly diagnosed with MOG antibody-associated disease generally face a low risk of relapse and lasting disability. The research was published in the journal Neurology.

People newly diagnosed with myelin oligodendrocyte glycoprotein antibody-associated disease, or MOGAD, generally had a low risk of relapse and lasting disability, according to a Kaiser Permanente study. The work is published in the journal Neurology.